Defining the clinical validity of genes reported to cause pulmonary arterial hypertension
Genetics in Medicine · 2023-11 · 25 (11) · 100925
DOI: 10.1016/j.gim.2023.100925 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genetics in Medicine, 2023-11. Verfasst von Carrie L Welch und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Columbia University Irving Medical Center, New York, NY. Hauptthemen laut MEDLINE: Pulmonary Arterial Hypertension, Hypertension, Pulmonary. Die Arbeit wurde bisher 88-mal zitiert (Crossref) und nennt 181 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, British Heart Foundation, NHGRI NIH HHS.
Abstract (Originalsprache)
PURPOSE: Pulmonary arterial hypertension (PAH) is a rare, progressive vasculopathy with significant cardiopulmonary morbidity and mortality. Genetic testing is currently recommended for adults diagnosed with heritable, idiopathic, anorexigen-, hereditary hemorrhagic telangiectasia-, and congenital heart disease-associated PAH, PAH with overt features of venous/capillary involvement, and all children diagnosed with PAH. Variants in at least 27 genes have putative evidence for PAH causality. Rigorous assessment of the evidence is needed to inform genetic testing. METHODS: An international panel of experts in PAH applied a semi-quantitative scoring system developed by the NIH Clinical Genome Resource to classify the relative strength of evidence supporting PAH gene-disease relationships based on genetic and experimental evidence. RESULTS: Twelve genes (BMPR2, ACVRL1, ATP13A3, CAV1, EIF2AK4, ENG, GDF2, KCNK3, KDR, SMAD9, SOX17, and TBX4) were classified as having definitive evidence and 3 genes (ABCC8, GGCX, and TET2) with moderate evidence. Six genes (AQP1, BMP10, FBLN2, KLF2, KLK1, and PDGFD) were classified as having limited evidence for causal effects of variants. TOPBP1 was classified as having no known PAH relationship. Five genes (BMPR1A, BMPR1B, NOTCH3, SMAD1, and SMAD4) were disputed because of a paucity of genetic evidence over time. CONCLUSION: We recommend that genetic testing includes all genes with definitive evidence and that caution be taken in the interpretation of variants identified in genes with moderate or limited evidence. Genes with no known evidence for PAH or disputed genes should not be included in genetic testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Columbia University Irving Medical Center, New York, NY.
- Division of Pulmonary, Critical Care, Sleep and Occupational Medicine, Indiana University School of Medicine, IN.
- Department of Genetics, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands.
- Center for Pulmonary Hypertension, Thoraxklinik-Heidelberg gGmbH, at Heidelberg University Hospital and Translational Lung Research Center, German Center for Lung Research, Heidelberg, Germany; Laboratory for Molecular…
- NIHR BioResource for Translational Research - Rare Diseases, Department of Haemotology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom; Department of Medicine, School of Clinical Medicin…
- Department of Human Genetics, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
Förderung
- NHLBI NIH HHS
- British Heart Foundation
- NHGRI NIH HHS
- Wellcome Trust
- Instituto de Salud Carlos III
- Alberta Mennega Stichting
- National Institutes of Health
- National Heart, Lung, and Blood Institute
Zitieren
APA
Welch, C. L., Aldred, M. A., Balachandar, S., Dooijes, D., Eichstaedt, C. A., Gräf, S., Houweling, A. C., Machado, R. D., Pandya, D., Prapa, M., Shaukat, M., Southgate, L., Tenorio-Castano, J., ClinGen PH VCEP, Chung, W. K., & International Consortium for Genetic Studies in Pulmonary Arterial Hypertension (PAH-ICON) at the Pulmonary Vascular Research Institute (PVRI) (2023). Defining the clinical validity of genes reported to cause pulmonary arterial hypertension. Genetics in Medicine, 25(11), 100925. https://doi.org/10.1016/j.gim.2023.100925
Vancouver
Welch CL, Aldred MA, Balachandar S, Dooijes D, Eichstaedt CA, Gräf S, et al. Defining the clinical validity of genes reported to cause pulmonary arterial hypertension. Genetics in Medicine. 2023;25(11):100925. doi:10.1016/j.gim.2023.100925
BibTeX
@article{Welch2023,
author = {Welch, Carrie L and Aldred, Micheala A and Balachandar, Srimmitha and Dooijes, Dennis and Eichstaedt, Christina A and Gräf, Stefan and Houweling, Arjan C and Machado, Rajiv D and Pandya, Divya and Prapa, Matina and Shaukat, Memoona and Southgate, Laura and Tenorio-Castano, Jair and ClinGen PH VCEP, ClinGen PH VCEP and Chung, Wendy K and International Consortium for Genetic Studies in Pulmonary Arterial Hypertension (PAH-ICON) at the Pulmonary Vascular Research Institute (PVRI), International Consortium for Genetic Studies in Pulmonary Arterial Hypertension (PAH-ICON) at the Pulmonary Vascular Research Institute (PVRI)},
title = {Defining the clinical validity of genes reported to cause pulmonary arterial hypertension},
journal = {Genetics in Medicine},
year = {2023},
volume = {25},
number = {11},
pages = {100925},
doi = {10.1016/j.gim.2023.100925}
}
EUVIMED